Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA 2021 Global Annual Meeting
Are You Ready for a NISS? Industry and Regulatory Perspectives on the US FDA Newly Identified Safety Signal Process
Session Chair(s)
Jamie Wilkins, PharmD
- Senior Director, Head - Risk Management Center of Excellence-Worldwide Safety
- Pfizer Inc, United States
This session will review FDA’s Newly Identified Safety Signal (NISS) process, and also assess its impact to industry. The impact assessment considers approaches to integrate signal detection methodology and internal processes to address a NISS.
Learning Objective : Describe the FDA Newly Identified Safety Signal (NISS) evaluation process; Explain the analysis of safety data sources, intake and analysis relevant to a NISS undertaken by a large pharmaceutical company; Identify key information within the session which could be used to formulate a plan to address a NISS received by the participant’s organization.
Speaker(s)
FDA Update
Jason Bunting, PharmD
- Science Policy Analyst, OCD, CDER
- FDA, United States

Industry Update
Bertha V Ferrer, MSc, RPh
- Senior Director, Head of Quality Management and Inspections
- Pfizer Inc, United States
Industry Update
Adrian Dana, MD
- Vice President, Global Patient Safety and Risk Management
- Aimmune Therapeutics, United States